Grey Wolf Therapeutics
PrivateLast Round
Series B
Extension
May 23, 2024
Total Funding Raised
$118.37M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Grey Wolf Therapeutics is a biotechnology company that develops novel antigen modulation therapies to treat cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Grey Wolf Therapeutics Comparables
Compare Grey Wolf Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeoPhore | 81% | |
| Enara Bio | 74% | |
| Pathios Therapeutics | 73% | |
Grey Wolf Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 23, 2024 | ||||
| Series B | Jan 26, 2023 | ||||
| Grant | May 18, 2021 | ||||
| Series A Extension | Jan 9, 2020 | ||||
| Series A | Feb 11, 2019 | ||||
Seed | Sep 1, 2017 |
Key People
Founding team and executive leadership
Grey Wolf Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andera Partners | Series B, Series A Extension, Series A, Series B Extension |
| Oxford Science Enterprises | Series B, Series B Extension |
| Intermediate Capital Group | Series B Extension |
| British Patient Capital | Series B, Series B Extension |
| Innovate UK | Grant |
| Canaan Partners | Series B, Series A Extension, Series B Extension, Series A |
| Oxford Science Enterprises | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 29, 2026
Partnered with genomics to develop autoimmune disease treatments.
- Apr 16, 2026
Edwin Moses joins as the new Chair.
Grey Wolf Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Grey Wolf Therapeutics's valuation, stock price, and market status.